Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands^*

References

• Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9
   PubMed Web of Science ®Google Scholar
• Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005;100:1685-93
   PubMed Web of Science ®Google Scholar
• Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12
   PubMed Web of Science ®Google Scholar
• Tramer MR, Moore RA, Reynolds DJ, et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82
   PubMed Web of Science ®Google Scholar
• Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update Arthritis Rheum 2000;43:1905-15
   Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55
   PubMed Web of Science ®Google Scholar
• Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998;93:2037-46
   PubMed Web of Science ®Google Scholar
• MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001;135:711-21
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81
   PubMed Web of Science ®Google Scholar
• Hartnell NR, Flanagan PS, MacKinnon NJ, et al. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada. Am J Geriatr Pharmacother 2004;2:171-80
   PubMedGoogle Scholar
• Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001;19:655-65
   PubMed Web of Science ®Google Scholar
• Rahme E, Toubouti Y, Lelorier J. Utilization and cost comparison of current and optimal prescribing of nonsteroidal antiinflammatory drugs in Quebec, Canada. J Rheumatol 2006;33:588-96
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Phillips CJ, et al. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord 2006;7:79
   PubMed Web of Science ®Google Scholar
• Stichting transmuraal netwerk Midden-Holland‘Guidelines NSAID use and prevention of GI events’ (Transmurale richtlijn NSAID-gebruik en preventie van maagschade). Gouda, The Netherlands: Stichting transmuraal netwerk netwerk Midden-Holland, 2005
   Google Scholar
• Moens HJ, van Croonenborg JJ, Al MJ, et al. [Guideline ‘NSAID use and the prevention of gastric damage’]. Ned Tijdschr Geneeskd 2004;148:604-8
   PubMedGoogle Scholar
• Wiersma T, Flikweert S, van den Bosch WJ. [Summary of the practice guideline ‘Rheumatoid arthritis’ (first revision) from the Dutch College of General Practitioners]. Ned Tijdschr Geneeskd 2004;148:559-64
   PubMedGoogle Scholar
• Vonkeman HE, Fernandes RW, van de Laar MA. Under-utilization of gastroprotective drugs in patients with NSAID-related ulcers. Int J Clin Pharmacol Ther 2007;45:281-8
   PubMed Web of Science ®Google Scholar
• Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 2004;38:760-3
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke TA, Dieleman JP, et al. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 2003;42 (Suppl 3):iii23-31
   PubMed Web of Science ®Google Scholar
• Barozzi N, Tett SE. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 2007;16:1184-91
   PubMed Web of Science ®Google Scholar
• Van Soest EM, Siersema PD, Dieleman JP, et al. Persistence and adherence to proton pump inhibitors in daily clinical practice. Aliment Pharmacol Ther 2006;24:377-85
   PubMed Web of Science ®Google Scholar
• Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Utrecht University, 1993
   Google Scholar
• Schnitzer TJ, Kong SX, Mavros PP, et al. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 2001;23:1984-98
   PubMed Web of Science ®Google Scholar
• Catalan V, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value in Health 2000;3:417-26
   PubMedGoogle Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO, 1999
   Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2003;18:1137-47
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Van Soest EM, Sturkenboom MC, Dieleman JP, et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 2007;26:265-75
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 2006;4:1337-45
   PubMed Web of Science ®Google Scholar
• Singh G. A new safety warning: decreased gastroprotection is associated with an increase of serious ulcer complications in elderly users of NSAIDS. Gut 2007;56:28
   Google Scholar
• Florentinus SR, Nielsen MW, van Dijk L, et al. Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. Eur J Clin Pharmacol 2005;61:157-9
   PubMed Web of Science ®Google Scholar
• Sukel MPP, van der Linden MW, Chen C, et al. Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. Pharmacoepidemiol Drug Saf 2008;17:9-19
   PubMed Web of Science ®Google Scholar
• Thiebaud P, Patel BV, Nichol MB. Impact of Rofecoxib Withdrawal on Cyclooxygenase-2 Utilization among Patients with and without Cardiovascular Risk. Value Health 2006;9:361-8
   PubMed Web of Science ®Google Scholar
• Agrawal N. Risk factors for gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs). J Fam Pract 1991;32:619-24
   PubMed Web of Science ®Google Scholar
• Cham E, Hall L, Ernst AA, et al. Awareness and use of over-the-counter pain medications: a survey of emergency department patients. South Med J 2002;95:529-35
   PubMed Web of Science ®Google Scholar
• Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-24
   PubMed Web of Science ®Google Scholar
• Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 2003;125:389-95
   PubMed Web of Science ®Google Scholar
• Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994;47:731-7
   PubMed Web of Science ®Google Scholar